Pancreatic cancer: The potential clinical relevance of alterations in growth factors and their receptors

Journal of Molecular Medicine

Volumn 74, Issue 1, 1996, Pages 35-42

  Friess, H ^a   Berberat, P ^a   Schilling, M ^a   Kunz, J ^a   Korc, M ^b   Buchler M W ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adhesion molecules; Gene mutations; Growth factor receptors; Growth factors; Pancreatic cancer

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; PROTEIN P53; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA;

GENE EXPRESSION; HUMAN; HUMAN TISSUE; MOLECULAR BIOLOGY; PANCREAS CANCER; REVIEW;

EID: 0030024411     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00202070     Document Type: Review

References (16)

1. Aaronson, SA (1991) Growth factors and cancer. Science 254:1146-1153
2. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucheo M (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53:549-554
3. Andrén-Sandberg A (1990) Treatment with an LHRH analogue in patients with advanced pancreatic cancer. Acta Chir Scand 156:549-551
4. Barton CM, Hall PA, Hughes CM, Gullick WJ, Lemoine NR (1991) Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J Pathol 163:111-116
5. Barton CM, Staddon SL, Hughes CM, Hall PA, O'Sullivan C, Klöppel G, Theis B, Rüssel RCG, Neoptolemos J, Williamson RCN, Lane DP, Lemoine NR (1991) Abnormalities of the p53 tumor suppressor gene in human pancreatic cancer. Br J Cancer 64:1076-1082
6. Bellosta P, Talarico D, Rogers D, Basilico C (1993) Cleavage of K-FGF produces a tuncated molecule with increased biological activity and receptor binding affinity. J Cell Biol 121:705-713
7. 1 transition. Proc Natl Acad Sci USA 84:6770-6774
8. Büchler M, Friess H, Schultheiss KH, Gebhardt C, Kübel R, Muhrer KH, Winkelmann M, Wagener T, Klapdor R, Kaul M, Müller G, Schulz G, Beger HG (1991) A randomized controlled trial of adjuvant immuno-therapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer. Cancer 68:1507-1512
9. Büchler M, Ebert M, Beger HG (1993) Grenzen chirurgischen Handelns beim Pankreaskarzinom. Langenbecks Arch Chir Suppl:460-464
10. Bugler B, Amalrie F, Prats H (1991) Alternative initiation of translation determines cytoplasmic or nuclear localization of basic fibroblast growth factor. Mol Cell Biol 11:573-577
11. Burgess WH, Maciag T (1989) The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 58:575-606
12. Caldas C, Hahn SA, Hurban RH, Redston MS, Yeo CJ, Kern SE (1994) Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 54:3568-3573
13. Caron de Fromentel C, Soussi T (1992) TP 53 Tumour suppressor gene: a model for investigating human mutagenesis. Genes Chromosom Cancer 4:1-15
14. Casey G, Yamanaka Y, Friess H, Kobrin MS, Lopez ME, Buchler M, Beger HG, Korc M (1993) p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett 69:151-160
15. Chandrasekar B, Korc M (1992) Binding and biological actions of acidic and basic fibroblast growth factors in isolated rat pancreatic acini. Gastroenterology 102:A725 (abstract)
16. Chen P-L, Chen Y, Brookstein R, Lee W-H (1990) Genetic mechanisms of tumor suppression by the human p53 gene. Science 250:1576-1580